Why the hip is harder to reach than other joints

For patients wondering whether a collagen scaffold injection is a realistic alternative to theatre-based treatment, the hip presents a specific challenge that knees and shoulders do not. The femoral head — the ball at the top of the thigh bone — sits several centimetres beneath layers of thick muscle and soft tissue. In the knee or shoulder, bony landmarks sit close to the skin surface, making needle placement far more straightforward. At the hip, those same surface landmarks offer little reliable guide to what lies beneath them.

This depth matters because published orthobiologics literature suggests that landmark-only needle placement into deep joints misses the intra-articular target in roughly 30% of attempts, owing to natural variation in individual anatomy. For a simple pain-relieving injection, a near-miss may still deliver partial benefit. For an injectable scaffold material designed to bond to a specific cartilage defect and gel in place, depositing the product outside the joint capsule wastes the treatment entirely and achieves nothing therapeutically useful.

That combination — depth, anatomical variability, and a product that must land precisely — explains why hip cartilage procedures have historically defaulted to operating-theatre settings, whether fluoroscopy-guided or arthroscopic. The practical question for suitable patients is therefore not only whether an injectable scaffold can repair focal hip cartilage, but whether the hip joint can be accessed accurately enough, outside a theatre, for the treatment to work.

How ultrasound guidance converts a deep joint into an outpatient target

Ultrasound guidance resolves the access problem through a straightforward principle: the clinician watches the needle on a screen, in real time, as it advances through each tissue layer from skin to joint capsule. There is no guesswork about depth or trajectory — tip position is confirmed before any material is deposited.

At the hip, two reliable sonographic landmarks make this targeting feasible in experienced hands: the femoral neck and the anterior joint capsule are clearly visible on ultrasound in most patients, providing a consistent anatomical reference regardless of how deeply the joint sits beneath overlying muscle. Once the needle tip is confirmed to lie within the joint space, an injectable scaffold can be delivered with confidence that it will reach its intended site.

The two traditional alternatives each carry practical costs that sit poorly with a routine injection appointment. Fluoroscopy provides sharp bony landmark imaging but uses ionising radiation — a relevant consideration for patients who may require repeat imaging assessments over time. Arthroscopy offers direct visualisation of the joint interior but demands surgical incisions, a general or spinal anaesthetic, and an operating theatre; those requirements define a surgical pathway, not an outpatient appointment.

Ultrasound carries neither burden. Used in a clinic room with a portable imaging unit, it relies on sound waves rather than radiation and requires no incisions or theatre access. That combination of real-time precision and practical simplicity is what makes the hip — historically one of the more demanding joints to reach reliably — a viable target for injectable scaffold treatment as a focused outpatient session.

What ChondroFiller is and what happens inside the joint after injection

ChondroFiller Liquid begins as a fluid — thin enough to pass through a needle — and becomes a stable hydrogel within minutes of entering the warm joint environment. That temperature-triggered transition from liquid to gel is what makes needle delivery viable without any surgical preparation of the joint surface.

The material is a Type I collagen solution produced through a non-enzymatic, weak-acid extraction process. That method matters because it preserves intact the telopeptide domains — short sequences at the ends of the collagen molecule — responsible for physiological cross-linking. Conventional pepsin-cleaved collagens lose these regions and assemble less completely; the extraction process here is specifically designed to retain the self-assembly capacity that native tissue relies on.

Once gelled, the scaffold adheres to the cartilage surface and creates a structural environment that the body can work with. Evidence suggests that host stem cells, drawn from surrounding tissue, migrate into the matrix and over time begin differentiating toward cartilage-like tissue, which gradually replaces the resorbing collagen scaffold. No synthetic material persists permanently; the architecture is temporary and biological, designed to be replaced rather than to remain.

That biological integration is what sets ChondroFiller apart from the two injectable comparators most patients encounter in clinic. Hyaluronic acid acts as a temporary joint lubricant cleared by the body within weeks; it provides no scaffold for tissue repair. Synthetic polyacrylamide hydrogels occupy joint space and may modify pain signalling, but are non-regenerative and non-integrating — the material neither bonds to cartilage nor recruits cells into it. ChondroFiller's CE marking as a Class III medical device — the highest regulatory tier for implantable devices under EU and UK law — reflects precisely this active, integrating biological role, and is the regulatory basis on which it is distinguished from lubricant or volume-filling injectables.

Which hip patients are suitable — and who is not

The clearest way to think about suitability is to picture the nature of the damage. ChondroFiller is designed for a focal defect — a defined patch where cartilage has worn to Grade III or IV depth (meaning damage that extends more than halfway through the cartilage layer, or all the way down to underlying bone) while the surrounding cartilage remains largely intact. That intact rim acts as a natural border, holding the injected scaffold in place as it gels and integrates. Without it, reliable retention becomes uncertain.

Hip joints damaged by femoroacetabular impingement (FAI), sporting impact, or repetitive mechanical stress often produce exactly this pattern: a concentrated zone of wear in an otherwise relatively preserved joint, making a proportion of these patients potentially suitable candidates.

The picture is different in diffuse osteoarthritis affecting the whole joint surface. Where wear is widespread and no intact border remains, the structural conditions for scaffold retention are generally not met. ChondroFiller is not considered appropriate for end-stage, joint-wide disease.

Pre-injection MRI — using cartilage-sensitive sequencing — is required to map defect size, depth, and the condition of surrounding tissue before any treatment decision is made. Patients with inflammatory joint disease, active joint infection, or certain systemic conditions will need individual clinical assessment; the injection is not appropriate for every hip pain presentation.

Patients who want to explore whether this pathway may be relevant for their situation can complete an online suitability assessment at amsk.co.uk.

What the clinical evidence shows — and where gaps remain

Published clinical series across joints report consistent results over more than a decade of use. In multi-joint studies covering over 20,000 implantations, IKDC functional scores have improved by approximately 30 points at the 12-month mark, and MOCART imaging scores — which assess cartilage fill and surface integration — have ranged from 70 to 87. Complication rates have been reported as negligible, and reoperation rates in the region of 3–8%. These figures derive from observational series rather than randomised controlled trials, and should be read in that context; they nonetheless represent a substantial accumulated dataset on scaffold safety and performance across the knee, hip, ankle, and other joints.

Hip-specific evidence is more limited. Perez-Carro et al. (2021) provides a published contribution focused on the hip joint and is the most directly applicable clinical reference currently available for this indication. No randomised controlled trial evidence for ChondroFiller specifically in the hip has been published, and the hip evidence base remains thinner than the accumulated knee data — a distinction that matters when interpreting what the literature can and cannot yet confirm about hip-specific outcomes.

The multi-joint data does offer a meaningful signal about scaffold behaviour, biological integration, and the material's safety profile. For patients with a focal hip cartilage defect who are exploring their options, the existing published evidence is sufficient to support a considered, well-informed conversation with a clinician — without either overstating what is established or dismissing a decade of consistent multi-joint findings.

What an outpatient hip injection appointment typically involves

For most patients, the most reassuring aspect of this pathway is how straightforward the appointment itself turns out to be.

A session typically begins with a review of existing MRI to confirm defect location and map its boundaries in relation to the planned needle approach. Once the target is agreed, the skin is prepared and the needle advanced to the hip joint capsule under continuous ultrasound guidance. The scaffold is then injected into the defect zone; intravenous antibiotic cover is administered as standard protocol at this stage.

The procedure component takes tens of minutes rather than hours — no general anaesthetic is required and no overnight stay. Patients return home the same day.

Some degree of joint soreness in the days following is common and expected. Specific guidance on loading and activity levels is provided based on defect location and size; this is not a one-size prescription.

A follow-up assessment at around six weeks is standard practice. At that point, early tissue response can be evaluated, activity progression discussed, and a decision made on whether additional imaging is warranted. For patients who respond as expected, the six-week mark often represents the transition toward graduated return to everyday activities — more demanding loading is typically considered over a longer horizon thereafter.

For patients whose defect pattern does not suit this injection pathway, surgical options remain available; the two routes are not mutually exclusive. An online suitability assessment can help clarify which pathway merits further clinical discussion — available at amsk.co.uk.